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Abstract: Anthracycline compounds including daunorubicin are the foundation of many modern 
chemotherapeutic regimens. However, the side-effects of these compounds can be severe, leading 
to alopecia, nausea, immune deﬁ  ciency, and cardiotoxicity. For immunocompromised patients 
with aggressive Kaposi’s sarcoma (KS), these complications often preclude the completion of 
appropriate chemotherapeutic regimens. This review focuses on the development and efﬁ  cacy of 
liposomal daunorubicin (DaunoXome®; DNX) carriers for the treatment of KS. Encouragingly, 
DNX demonstrated increased in vivo stability and speciﬁ  city. As a result, KS patients beneﬁ  t 
from higher cumulative chemotherapeutic doses without signiﬁ  cant cardiotoxicity. Tumor 
response to DNX treatment surpasses that of non-encapsulated daunorubicin and is similar to 
that observed with conventional multi-drug therapies such as ABV (doxorubicin, bleomycin, 
vincristine). Moreover, some reports indicate the patient quality of life during therapy may 
improve with DNX treatment. Although the development of DNX represents a signiﬁ  cant 
advance in KS therapy, recent data suggest that additional modiﬁ  cation of the liposomal carrier 
to include pegylation or target speciﬁ  c antibodies may further increase daunorubicin efﬁ  cacy 
in the future. 
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Kaposi’s sarcoma
Originally described in the late nineteenth century, Kaposi’s sarcoma (KS) has become 
the most prevalent cancer amongst AIDS patients in the US and worldwide (Engels et 
al 2006). Until recently the etiological agent of this disease remained elusive. Finally, 
in 1994, Chang and colleagues isolated viral DNA sequences from KS biopsies, result-
ing in the identiﬁ  cation of the Kaposi’s sarcoma-associated herpes virus (KSHV or 
HHV-8) (Chang et al 1994). KSHV is maintained latently in all KS tumors and thus 
is believed to be the causative agent of the disease (Chang et al 1994; Cesarman et al 
1995; Soulier et al 1995). Several forms of KS are currently recognized, including 
classic, endemic, iatrogenic (transplant associated), and AIDS-associated (Tappero 
et al 1993). Among the few cases of KS reported in the US prior to the onset of the 
AIDS epidemic, most were iatrogenic or found in elderly men of Mediterranean descent 
(classic). In contrast, endemic KS has always been prevalent in Africa, and today has 
become the most frequently observed pediatric cancer in this population following 
the rise of the HIV epidemic. AIDS-associated KS ﬁ  rst became prevalent worldwide 
during the 1980s into the early 1990s in men who have sex with men. It has declined 
following the implementation of highly active anti-retroviral therapy (HAART), as 
have many other of the original AIDS-deﬁ  ning conditions (Eltom et al 2002; Casper 
2006; Engels et al 2006). Unfortunately, HAART has had no effect on the incidence 
of classic, iatrogenic, or endemic KS nor is HAART available to populations who 
presently experience the highest prevalence of HIV, such as in Africa. More alarming, 
cases of AIDS-associated KS are now emerging in patients receiving HAART and who 
maintain adequate immune function (Koon et al 2005; Boshoff 2006; Casper 2006). International Journal of Nanomedicine 2007:2(3) 278
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As the number of HIV-positive individuals continues to 
grow worldwide, KS is re-emerging as a more aggressive 
and prominent tumor type.
The changing nature of KS is reﬂ  ected in 5-year survival 
data reported by the NCI Surveillance Epidemiology and 
End Results (SEER) program (Figure 1). As mentioned 
above, most KS cases in the US prior to 1980 were dermal, 
minimally aggressive, and often associated with elderly 
white men. For these patients, KS was rarely life threaten-
ing and over 80% survived more than 5 years. During the 
height of the US HIV epidemic and prior to the onset of 
HAART, a more aggressive KS tumor emerged. Dramati-
cally, 5-year survival rates in KS patients plummeted from 
1985 to 1989. Following the implementation of HAART 
and the development of KS-speciﬁ  c treatment regimens 
(interferon alpha, taxol, and combination chemotherapy) 
the US witnessed a substantial decrease in patient mortality. 
Yet, even today, less than 50% of all KS patients in the US, 
ie, with ready access to HAART, reach the 5-year survival 
mark. The outlook is even worse for the growing number 
of African American KS patients. Clearly, our ability to 
treat KS patients both now and in the future is dependent 
upon the development of novel and efﬁ  cacious treatment 
regimens against KS. Restoring immune sufﬁ  ciency alone 
does not sufﬁ  ce.
Current KS therapy ranges from watchful waiting to 
aggressive chemotherapy and is largely dependent upon the 
lesion location, size, and extent. Localized, non-progressive 
disease is easily treated through cryotherapy, argon laser 
excision, local chemotherapeutic injection, or localized 
radiation. Response rates vary with each of these treatment 
regimens, but have been reported to reach up to 90% (Krown 
et al 2004). For AIDS-associated and iatrogenic KS, immune 
reconstitution is sometimes sufﬁ  cient to trigger tumor re-
mission. HAART alone caused KS remission in 48%–86% 
of HIV positive KS patients (Lebbe et al 1998; Dupin et al 
1999; Dupont et al 2000; Cattelan et al 2001; Murdaca et al 
2002; Paparizos et al 2002; Wilkinson et al 2002). Similarly, 
iatrogenic KS can be controlled by limiting the dosage, or 
switching the type of immunosuppressive therapy employed. 
However, recent evidence suggests that immune reconstitu-
tion is not the sole factor leading to KS regression. Protease 
inhibitors associated with modern day HAART may also 
possess anti-KS activities (Monini et al 2004). Moreover, our 
recent ﬁ  ndings along with those reported by Stallone et al 
suggest that some immunosuppressive drugs like rapamycin 
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Figure 1 KS survival rates during the rise of the HIV/AIDS pandemic. Data bars represent the percentage of individuals reported by the NCI Surveillance Epidemiology and 
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may speciﬁ  cally target KSHV-infected tumors (Stallone et al 
2005; Sin et al 2006).
Visceral organ involvement represents the most severe 
manifestation of KS, and lesions have been reported in 
the lungs, gastrointestinal tract, lymph nodes, heart, bone, 
and spleen of affected individuals (Krown et al 2004). 
For such disseminated or rapidly progressing forms of KS 
more aggressive therapies must be employed. Classically, 
a combination of multiple chemotherapeutics has been 
utilized (eg, CHOP – cyclophosphamide, hydroxydoxorubi-
cin, vincristine/Oncovin®, prednisone; ABV – doxorubicin, 
bleomycin, vincristine; and BV – bleomycin, vincristine). 
Alternatively, interferon alpha, paclitaxol, and etoposide 
effectively treat disseminated KS and are FDA-approved for 
this purpose (Real et al 1986; Lane et al 1988; Krown et al 
1993; Welles et al 1998; Gill et al 1999; Evans et al 2002). 
However, the side-effects of chemotherapeutic drug regimens 
limit their efﬁ  cacy, especially in immunocompromised KS 
patients. Anthracycline drugs in particular (eg, doxorubicin, 
epirubicin, idarubicin, daunorubicin) present a secondary 
challenge to patient health due to their known cardiotoxic 
side-effects (Elliott 2006). In order to combat these issues, 
targeted drug delivery systems have been developed for 
several anthracycline compounds. This review focuses 
on the pharmaceutical advancements that have aimed to 
improve both the efﬁ  cacy and tolerability of daunorubicin 
in KS treatment. 
Daunorubicin
Originally isolated from Streptomyces peucetius varcaesitue, 
daunorubicin (DNR) has become a mainstay in modern 
chemotherapy (Dimarco et al 1964; Behal 2000). DNR 
belongs to the anthracycline family of compounds, which 
hold intrinsic antibiotic and anti-tumor activities. Structur-
ally, anthracyclines contain a daunosamine sugar linked to 
naphthacene via an O-glycosidic bond (see Figure 2) (Robert 
1998). Differences in the naphthacene derivative differentiate 
DNR from other anthracyclines and change the pharmaco-
kinetic properties of the compound (Robert 1998). DNR is 
believed to function through multiple mechanisms to mediat-
ed DNA damage (Sinha and Politi 1990). Intercalation of the 
daunosamin residue into the minor groove of cellular DNA 
leads to local DNA unwinding (Crooke et al 1978; Chaires 
et al 1982; Chaires 1990; Nabiev et al 1991; Belloc et al 
1992). It is hypothesized that these DNA–DNR complexes 
serve as a blockade for cellular replication. Alternatively, 
the activity of topoisomerase II, an enzyme that relieves 
torsional stress during DNA synthesis, is also signiﬁ  cantly 
inhibited by DNR (Tewey et al 1984; Froelich-Ammon and 
Osheroff 1995). Anthracyclines stabilize interaction between 
topoisomerase II and cleaved DNA, preventing the enzyme 
from fully resolving DNA breaks (Tewey et al 1984). Finally, 
cellular metabolism of DNR leads to the formation of free 
radical species capable of inducing DNA damage (Handa and 
Sato 1975; Doroshow and Davies 1986; Sinha 1989). Thus, 
through the non-speciﬁ  c targeting of DNA replication, DNR 
targets all cells with a high proliferation index. Cell cycle 
progression prior to complete repair of these DNR-induced 
DNA lesions can result in chromosomal instability or trig-
ger cell death. Since normal cells of the body must also 
proliferate to maintain homeostasis, signiﬁ  cant side-effects 
including alopecia, nausea, and vomiting are often observed 
in patients receiving DNR therapy. In order to alleviate some 
of these adverse side-effects, a liposomal DNR derivative 
was developed.
Liposomal formulation
Phospholipid spheres were originally discovered and termed 
liposomes in the 1960s (Bangham et al 1965; Sessa and 
Weissmann 1968). Now tailored for use in drug formula-
tions, liposomes can be classiﬁ  ed based on lamellarity, 
size, makeup, and biological distribution (Hofheinz et al 
2005; Netageri 1993). Unilaminar liposomes, composed of a 
single lipid bilayer, are frequently used to encapsulate water 
soluble drugs (Hofheinz et al 2005), and can be further clas-
siﬁ  ed based on size. Small unilaminar liposomes (SUV) are 
typically 25  –100 nm in diameter, whereas large unilaminar 
liposomes (LUV) are signiﬁ  cantly bigger (100–400 nm) 
(Netageri 1993). Multilaminar liposomes (MLV) range from 
100 nm to over 1 μm in size and contain several concentric 
lipid bilayers (Netageri 1993). In contrast to SUV and LUV, 
MLV are used frequently to package lipid soluble drugs 
(Hofheinz et al 2005).
The liposomal structure is hypothesized to stabilize 
encapsulated drugs in vivo. Liposomes ﬂ  owing in the blood 
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fail to extravasate intact blood vessels, accumulating instead 
in areas of discontinuous capillaries, such as tumor tissue 
(Jain 1987; Dvorak et al 1988; Huang et al 1992; Hobbs 
et al 1998). In this manner, therapeutic toxicity should be 
reduced while increasing tumor uptake. Moreover, since KS 
is a highly vascularized tumor characterized by capillary 
leakage, this property of liposomal drug formulations may 
increase therapeutic efﬁ  cacy. Unfortunately, all liposomes 
also naturally target the reticuloendothelial system (RES) of 
the body, which includes the liver, spleen, and bone marrow 
(Patel and Russell 1988; Huang et al 1992). While circulating 
in the blood, liposomes bind plasma proteins, immunoglobu-
lins, and complement leading to RES-uptake via opsiniza-
tion (Chonn et al 1992; Cullis et al 1998). Extremely large 
liposomes, like the giant MLVs (>1 μm), are also trapped 
and concentrated within the small, alveolar capillaries of 
the lungs (Hwang 1987). Certainly, it could be envisioned 
that liposomal uptake by the RES would have signiﬁ  cant 
advantages for the delivery of potential immunomodula-
tory therapeutics. However, for most anti-cancer agents this 
property is undesirable. 
Several RES-targeting liposomal drug formulations 
have been developed using a wide variety of strategies. 
These drugs have advantages over classic therapies, reduc-
ing a number of the toxicities previously associated with 
anthracycline administration (Roerdink 1987). Some of the 
ﬁ  rst forms of liposomal doxorubicin (LD) employed acidic 
lipids to draw in the weakly basic drug (Allen 2004). Other 
approaches establish a liposomal pH gradient, pulling the 
drug towards the core of each lipid sphere (Mayer et al 1986; 
Li et al 1998). Such technology is utilized in the formulation 
of therapeutics currently on the market including Myocet® 
(LD; Medeus Pharma) and Onco TCS® (liposomal vincris-
tine; INEX Parmaceuticals) (Embree et al 1998; Gelmon 
et al 1999; Allen and Martin 2004). Finally, RES-targeting 
liposomes can be formulated to contain lipid-soluble drugs 
within the liposomal membrane. Notably, LEP ETU®, a 
form of liposomal paclitaxel manufactured by NeoPhar, is 
manufactured using this technology (Treat et al 2001; Allen 
and Martin 2004).
As scientists learn more about the biological properties of 
liposomes, it has become feasible to develop RES-avoiding 
drug formulations. Clearly, a reduction in RES uptake pro-
vides many pharmacokinetic and biological beneﬁ  ts to any 
chemotherapeutic. Toxicity, speciﬁ  city, and plasma half-life 
are increased by RES avoidance. Several methodologies 
have been developed that limit RES exposure. Most simply, 
patients may be subjected to RES saturation with empty 
liposomes prior to therapeutic administration. This approach 
limits RES uptake but may have signiﬁ  cant, long-term effects 
on RES function (Abra et al 1980; Allen 1988). Modeling 
the RES avoidance by erythrocytes, scientists have incorpo-
rated polyethylene glycol (PEG) in the lipid bilayer of some 
liposomes. This “stealth” technology greatly extends the 
drug half-life through a reduction in RES uptake (reviewed 
in Allen and Martin 2004). Doxil, a PEG-coated form of 
liposomal doxorubicin (PLD), is the ﬁ  rst FDA-approved KS 
therapy to employ STEALTH® technology (see Figure 3). 
This approach as well as other RES-avoiding technologies 
including DaunoXome® (liposomal daunorubicin; DNX) 
have been highly successful and represent a wave of newly 
formulated liposomal therapeutics.
Already new technology is being developed to further the 
targeting speciﬁ  city of liposomal carriers. Cationic liposomes 
show high afﬁ  nity for tumor neovasculature and may dem-
onstrate increased efﬁ  cacy for highly angiogenic tumor types 
(Thurston et al 1998). In addition, scientists are working to 
incorporate speciﬁ  c receptors, tumor ligands, and antibodies 
in future liposomal drug formulations. These modiﬁ  cations 
should lead to the development of tumor-speciﬁ  c therapies 
with limited side-effects and maximum efﬁ  cacy.
Pharmacology and kinetics
DaunoXome®, a liposomal formulation of DNR (DNX), 
was ﬁ  rst licensed in the United Kingdom in 1995 and later 
approved by the FDA. This liposomal formulation, manu-
factured by Gilead Pharmaceuticals Inc. (San Dimas, CA), 
is uniquely formulated to be RES-avoiding. Speciﬁ  cally, 
DNX is the ﬁ  rst liposomal derivative of its kind to be made 
solely of lipids (Allen and Martin 2004). Composed of three 
major components: distearoylphosphatidylcholine (DPC), 
cholesterol, and DNR, DNX liposomes are small (45 nm) and 
neutrally charged (Gilead Sciences 2000; Allen and Martin 
2004). Formulation of DNR into a citrate salt assists in drug 
encapsulation. Due to the small size and relative neutrality 
of DNX particles, RES uptake is minimized, leading to 
prolonged drug circulation (Forssen et al 1992). However, 
in murine model systems, RES absorption of DNX remains 
60%–110% higher than that observed during conventional 
DNR therapy (Gilead Sciences 2000).
Evidence that the pharmacokinetics of DNX would differ 
greatly from those observed with conventional DNR ﬁ  rst came 
from murine xenograft models. In preclinical trials, mice with 
lymphosarcoma (P-1798)-derived tumors or mammary adeno-
carcinoma (MA16C)-derived tumors were treated and monitored 
for DNX pharmacokinetics (Forssen et al 1992). Plasma DNR International Journal of Nanomedicine 2007:2(3) 281
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levels were consistently higher in DNX-treated mice compared 
with conventional DNR. Clearance of free DNR occurred rapidly 
(44.9 mL/h) compared with the liposomal formulation (0.195 
mL/h). Although the rate of tumor drug accumulation was much 
higher in mice treated with conventional therapy (ka = 2.64/h) 
than those receiving DNX (ka = 0.265/h), area under the curve 
(AUC) values increased 10 times with the liposomal formulation. 
Differences in pulmonary and cardiac uptake were negligible, 
suggesting that toxicity to these organs would be limited. As 
a result, tumor progression as well as mortality signiﬁ  cantly 
decreased in DNX-treated mice. The authors attribute the plasma 
stability of liposomal DNR to the incorporation of high phase 
transition temperature of DPC and the addition of cholesterol 
to the encapsulating lipid bilayer. This stability is required to 
maintain elevated DNX serum levels long enough to allow 
for effective tumor uptake. Once entrapped in the fenestrated 
capillaries of the tumor, DNR becomes bioavailable and func-
tions to effectively limit tumor growth. These tumor-speciﬁ  c 
targeting properties made liposomal DNR attractive for future 
clinical studies.
Following the success of DNX in animal models, several 
clinical trials examined the pharmacokinetic properties of 
this novel drug formulation in patients. At the time, KS 
was emerging as a serious threat to the growing number of 
AIDS patients worldwide. Even though animal models of 
KS did not become available until recently (An et al 2006) 
and, therefore, DNX was never tested preclinically in a bona 
ﬁ  de KS-model, there was a strong push to get FDA approval. 
For this reason, the properties of DNX in KS patients were 
examined by several groups. The ﬁ  rst study, reported in 1995, 
examined the pharmacokinetics, response, and toxicity of 
increasing DNX dosages (Gill et al 1995). From these data, 
a dosage between 40 and 60 mg/m2 was shown to be most 
efﬁ  cacious. As a result the recommended DNX dosage was 
set to 40 mg/m2 every 2 weeks, a standard which still holds 
true today (Gilead Sciences 2000). At these levels, reports of 
mean plasma AUC range from 114.91 to 120.1 μg h–1 mL–1 
(Gill et al 1995; Fumagalli et al 2000). These data represent 
an 11- to 12-fold increase over conventional DNR and reﬂ  ect 
the stability of the liposomal carrier as previously described 
in murine model systems (Forssen et al 1992; Gill et al 
1995). Likewise, clearance is signiﬁ  cantly reduced in DNX 
treated patients when compared with those treated with con-
ventional drug (10.5 mL/min vs 233 mL/min, respectively) 
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(Alberts et al 1971; Gill et al 1995; Fumagalli et al 2000). 
These two properties combine to stabilize serum DNX, 
resulting in a half life between 4 and 5.6 h (t1/2 DNR ≈ 0.77 h) 
(Gill et al 1995; Fumagalli et al 2000). Peak plasma levels 
range from 14.8 to 22 μg/mL and far surpass those previously 
observed with conventional DNR treatment (Alberts et al 
1971; Gill et al 1995; Fumagalli et al 2000). These results 
suggest that the increased stability of liposomal DNR may 
provide a mechanism by which high cumulative doses may 
be administered to patients without serious side-effects. As 
a result, the efﬁ  cacy and tolerability of DNX was anticipated 
to surpass all previous DNR formulations.
Efﬁ  cacy in KS treatment
Evaluation of the efﬁ  cacy of an individual KS treatment 
modality is largely dependent upon the implementation 
of standard of staging criteria. Unfortunately, many of the 
initial DNX studies were conducted before the implementa-
tion of the Aids Clinical Trials Groups (ACTG) response 
criteria. In 1989 Krown et al proposed this standard method 
of staging to assess KS response to clinical trial regimens 
(Krown et al 1989). The scope of KS involvement is often 
difﬁ  cult to assess and may be confounded by other under-
lying conditions, especially in the context of HIV-AIDS. 
Determining the extent of visceral disease can be difﬁ  cult 
and in the past has been scored mainly upon the severity of 
patient symptoms. The ACTG criteria have deﬁ  ned a distinct 
and stringent set of characteristics to classify therapeutic 
response (see Table 1). Speciﬁ  cally, the appearance of any 
new lesion or the progression of any KS-related symptom 
excludes patients from achieving either complete or partial 
response even if as a whole, the individual experiences a 
therapeutic beneﬁ  t (Krown et al 1989). As a result of these 
stricter criteria, studies conducted using ACTG guidelines 
show a signiﬁ  cant decrease in patient response rates com-
pared with studies conducted using non-standard evaluation 
criteria (Gill et al 1996). Even with the implementation of the 
ACTG guidelines, many factors may inﬂ  uence the reported 
success rate of individual trials, including patient CD4 
count, treatment history, and concurrent drug administration 
(Presant et al 1993; Gill et al 1995; Fumagalli et al 2000; 
Rosenthal et al 2002).
The first DNX trials focused on the safety and 
potential therapeutic benefits of liposomal DNR in the 
treatment of AIDS-associated KS. Three separate phase 
I/II clinical trials monitored the response of over 115 
HIV-positive KS patients (Presant et al 1993; Gill et al 
1995; Tulpule et al 1998). The severity of KS varied 
greatly among the study participants, but most patients 
were classified as having highly aggressive disease. Pre-
vious treatment with chemotherapy was not used as an 
exclusion parameter. Once drug safety was established 
at lower doses (Presant et al 1993; Gill et al 1995), study 
participants were treated every 2 weeks with 40–60 mg/m2 
i.v. DNX. Overall response rates (representing those with 
complete or partial tumor regression), as determined by 
differential standards, varied from 55% to 60% (Presant 
et al 1993; Gill et al 1995; Tulpule et al 1998). Response 
Table 1 Aids Clinical Trials Groups response criteria for AIDS-releated Kaposi’s sarcoma 
Response classiﬁ  cation  Tumor-associated   Lesions  Visceral disease  Required response 
 edema      duration
Complete response (CR)  None  None¹  None²  4 weeks
Partial response (PR)  No increase or  1. 50% decrease in # or size  No increase or new  4 weeks
  new appearance  of previous lesions³ 2. No new  sites of involvement
    lesions or areas of involvement
    3. No increase 25% in the product
    of bidirectional indicator 
   lesion  diameterº
Stable disease (SD)  Any non-PR response  Any non-PR response  Any non-PR response  Not speciﬁ  ed
Progression  New edema or effusion  1. 25% increase in the size, #,   Any increase  Not speciﬁ  ed
    or sites of disease involvement 
   2.  25% change in lesion appearance 
    from macular to plaque-like/nodular
Notes:  As described in Krown et al 1989 ¹If brown/tan macular lesions persist, at least one representative must be biopsied and shown to be free of malignancy; 
²Veriﬁ  cation by restaging is required, otherwise only a clinical CR may be declared;  ³Deﬁ  ned as a 50% decrease in the sums of the products of the largest perpendicular 
diameters of bidimensionally measurable marker lesions and/or complete ﬂ  attening 50% of previously nodular lesions; ºIn patients with predominantly nodular lesions, 
ﬂ  attening of 75% is considered PR.International Journal of Nanomedicine 2007:2(3) 283
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of pulmonary KS alone was even higher, wherein 75% 
of study participants experienced complete or partial 
response according to ACTG standards (Tulpule et al 
1998). These results, which showed disease regression 
with few side-effects, provided a rationale to pursue DNX 
as a novel KS therapy. 
The ABV regimen is a classic ﬁ  rst-line defense against 
aggressive or disseminated KS. In clinical trials, the response 
rates to such combination drug therapy are reported to 
range from 33% to 88% (Krown et al 2004). To compare 
the efﬁ  cacy of DNX with conventional ABV, Gill and 
colleagues performed a prospective study of 227 HIV-
positive KS patients (Gill et al 1996). Study participants 
were randomized to two treatment arms, 40 mg/m2 DNX 
or ABV (10 mg/m2 doxorubicin, 15U bleomycin, 1 mg 
vincristine) every 2 weeks. Only patients with advanced 
KS and no prior systemic chemotherapy were admitted into 
the trial. All localized treatments had to be discontinued at 
least 14 days before study enrollment. Surprisingly, ACTG 
response rates between the two arms of the trial were com-
parable (25% and 27.9% for DNX and ABV, respectively) 
with most patients achieving stable disease (58%–62%). No 
signiﬁ  cant difference was observed in time to progression 
or survival. Complete remission was documented in both 
DNX- and ABV-treated study participants. Together, these 
data show that DNX efﬁ  cacy is not distinguishable from that 
of conventional, multi-drug ABV therapy.
 AIDS-associated KS represents a unique challenge 
wherein the decision to implement HAART in addition to 
chemotherapeutic regimens needs to be considered. In fact, 
in AIDS-associated lymphoma HAART can be delayed until 
all chemotherapy cycles have been concluded. Even though 
concomitant administration of HAART and combination-
chemotherapy is considered safe and effective (Ratner et al 
2001), the use of AZT with chemotherapy was previously 
contraindicated (Lim and Levine 2005). Importantly, with-
holding HAART during chemotherapy is safe, allows for 
the administration of higher dose therapy, and does not 
modulate AIDS progression (Little et al 2003). Whether these 
lymphoma-speciﬁ  c recommendations also applied to DNX 
administration in KS was previously unknown. 
 Protease inhibitors are known to block the activity 
of cytochrome p450IIIA4 (CYP3A4), which metabolizes 
anthracycline drugs (von Moltke et al 1998). Due to this 
property, the efﬁ  cacy of anthracyclin therapy in combina-
tion with HAART was formerly questioned. The emergence 
of HAART-resistant HIV strains has since led to the desire 
to maintain anti-retroviral treatment during the course of 
anthracycline administration. To determine the ramiﬁ  cations 
of proteasome inhibitor co-administration, Fumagalli and 
colleagues examined DNX pharmacokinetics in the presence 
or absence of HAART (Fumagalli et al 2000). Eighteen 
individuals with rapidly progressing visceral, pulmonary, 
gastrointestinal, or mucocutaneous KS were enrolled in 
the study. Of the participants, 39% had undergone prior 
chemotherapy. Although the pharmacokinetic properties of 
DNX (delivered at 40 mg/m2) were unaltered by concomi-
tant administration of any nucleoside reverse transcriptase 
inhibitor (NRTI)-protease inhibitor cocktail, prior anthra-
cycline therapy signiﬁ  cantly increased both peak DNX 
concentration and plasma AUC. These data suggest that prior 
chemotherapeutic treatments may inﬂ  uence DNX efﬁ  cacy. 
Regardless, most study participants (82.3%) achieved either 
complete or partial response. Together, these ﬁ  ndings suggest 
that HAART does not inﬂ  uence DNX efﬁ  cacy; however, 
the effect of anthracyline therapy on the activity of protease 
inhibitors remains to be addressed.
Although these trials demonstrate that DNX is efﬁ  cacious 
in the treatment of AIDS-associated KS, several patient 
attributes clearly effect therapeutic outcome. Recent reports 
suggest that prior administration of anthracyline therapy 
modulates both drug pharmacokinetics and KS response 
(Presant et al 1993; Gill et al 1995; Fumagalli et al 2000). 
Gill and colleagues examined this observation in detail, 
ﬁ  nding that prior chemotherapy as a whole does not inﬂ  u-
ence patient response (Gill et al 1995). However, in study 
participants previously treated with anthracycline therapies, 
a signiﬁ  cant difference in therapeutic efﬁ  cacy was observed 
(p = 0.004) (Gill et al 1995). Whether these observations can 
be attributed to therapeutic resistance or differences in DNX 
kinetics is unclear; however, it is clear that patient treatment 
history may inﬂ  uence the choice to begin liposomal DNR 
treatment. CD4 count also appears to affect DNX efﬁ  cacy. 
Patients with a CD4 count below 100 have a signiﬁ  cantly 
lower probability of responding to DNX therapy (p = 0.004), 
suggesting that control of HIV is essential to successful KS 
treatment (Gill et al 1995). Clearly, additional studies are 
required to assess the inﬂ  uence of these predisposing factors 
on DNX efﬁ  cacy. 
Tolerability and toxicity
Production of liposomal anthracycline compounds was 
pioneered with the goal of producing therapeutics with 
higher specificity and potency while limiting patient 
side-effects. A major concern of any anthracycline treatment 
modality is cardiotoxicity. Both congestive heart failure International Journal of Nanomedicine 2007:2(3) 284
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and cardiomyopathy have been reported to occur in a 
dose-dependent manner upon DNR treatment (Lefrak et al 
1973; Von Hoff et al 1979). To prevent the signiﬁ  cant 
complications associated with anthracycline cardiotoxicity, 
patient left ventricular ejection fraction (LVEF) is closely 
monitored. In general, individuals demonstrating an LVEF 
of less than 45% were excluded from all initial DNX stud-
ies (Gill et al 1996; Tulpule et al 1998). Direct comparison 
of cardiac function in patients treated with DNX vs ABV 
revealed no signiﬁ  cant difference in LVEF during treatment 
(Gill et al 1996). Only one report to date has documented 
any LVEF decline following DNX administration. More-
over, upon further review of the effected individual’s case 
history, prior anterior myocardial infarct was noted (Gill et 
al 1996). Thus, although cumulative doses in many trials 
reached levels of over 600 mg/m2 (Gill et al 1995, 1996; 
Tulpule et al 1998; Rosenthal et al 2002; Young et al 2004), 
DNX fails to induce signiﬁ  cant cardiotoxicity.
The most prominent DNX side-effect reported in all 
clinical trials was severe leukopenia, which was observed 
in 11%–17% of treatment cycles (Gill et al 1995; Fumagalli 
et al 2000). Most notably, in one trial, 85% of patients re-
ceiving a dose of 60 mg/m2 DNX every 2 weeks experienced 
grade 3/4 neutropenia (Tulpule et al 1998). Moreover, the 
increased incidence of leukopenia in DNX- vs ABV-treated 
individuals was statistically signiﬁ  cant (p = 0.021) (Gill 
1996). To combat this adverse effect, hemopoietic growth 
factors (eg, granulocyte colony-stimulating factor, G-CSF) 
were administered following 15%–29% of DNX treatment 
cycles and appeared to be effective in limiting further leu-
kopenia (Fugamalli 2000; Rosenthal 2002). Other severe 
DNX-speciﬁ  c side-effects were not observed.
DNX patients develop alopecia and neuropathy less 
frequently than those treated with other cytostatic regi-
mens (p < 0.0001) (Gill et al 1996). No other significant 
differences were found between patients treated with 
liposomal DNR vs conventional chemotherapy (Gill et 
al 1996). Specifically, nausea, fever, and fatigue were 
similar among treatment regimens (Gill et al 1996). 
In several reports, fever, flushing, and back pain were 
reported within the first 5 minutes of DNX administration. 
However, patients were typically able to resume therapy at a 
slower infusion rate without significant distress (Gill et al 
1996). Table 2 summarizes the complications observed 
in DNX trails for KS. Overall, DNX treatment appears 
to limit some of the adverse side-effects of conventional 
chemotherapy (Presant et al 1993; Gill et al 1995, 1996; 
Fumagalli et al 2000; Rosenthal et al 2002). 
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Several clinical trials have monitored patient quality of life 
(QOL) during DNX treatment. During one study, both physical 
and emotional performance increased over 70% during DNX 
treatment (Presant et al 1993). A second study comparing DNX 
with ABV showed that patients within the DNX study arm 
maintained QOL whereas QOL gradually declined with ABV 
treatment (Gill et al 1996). Although the signiﬁ  cance of these 
data is unclear, the trend suggests that DNX treatment may 
be more tolerable than conventional chemotherapy, especially 
during long-term treatment regimens.
Pharmacoeconomics
When considering any new medical intervention, the costs of 
therapy must be weighed against the potential beneﬁ  ts. For 
aggressive KS, several treatment options are now available, 
including conventional chemotherapies (eg, ABV, BV, 
CHOP), interferon alpha, vinca alkaloids, taxanes, and li-
posomal anthracyclines (reviewed in Krown et al 2004). In 
general, liposomal drug formulations are more costly than 
conventional chemotherapy and are at present unaffordable 
in the areas of greatest need such as in Africa. However, the 
potential for these drugs to signiﬁ  cantly reduce the adverse ef-
fects of anthracyclines make them attractive. To date, no direct 
comparison of PLD (Doxil®) with DNX has been conducted 
for KS, yet an indirect comparison can be made assuming 
that the patient cohorts and response criteria are essentially 
the equal. In 2008, Bennett and colleagues used data from 
the DNX vs ABV (Gill et al 1996) and PLD vs BV (Stewart 
et al 1998) trials to estimate the cost-effectiveness of each 
liposomal therapy. While DNX is clearly more affordable 
upfront (US$538/cycle vs US$1212/cycle with PLD) (Ben-
nett et al 1998), the number of cycles required for response as 
well as the costs associated with G-SCF administration must 
be included in order to properly compare the two therapies. 
During DNX treatment a higher number of patients required 
granulocyte-colony stimulating factor (G-SCF) therapy, in ad-
dition an average of 8.6 cycles of DNX vs 4.8 cycles of PLD 
were necessary for patient response (Gill et al 1996; Bennett et 
al 1998; Stewart et al 1998). Taking these factors into account, 
the cost of DNX treatment was still ~US$445 less than PLD 
(Bennett and Calhoun 2004).
In both studies, patient outcome was monitored by ATCG 
standards at the conclusion of the trial. Response rates for PLD 
vs DNX were 59% and 25%, respectively (Gill et al 1996; 
Stewart et al 1998). Due to this disparity among treatment 
regimens, the cost-effectiveness ratio (the cost associated 
with achieving one response) was twice as high for DNX 
(US$26,483) as for PLD (US$11,976) (Bennett et al 1998). 
In a study of Swedish patients, similar results were obtained, 
demonstrating that PLD is more cost effective than DNX for 
the treatment of KS (Hjortsberg et al 1999). 
Comments and conclusions
Treatment of aggressive KS has long relied upon the activity 
of combination chemotherapy. Although largely successful, 
these treatments carry many serious side-effects. The arrival 
of the liposomal anthracycline formulations provides patients 
new therapeutic options to combat KS. Herein, we discussed 
the pharmacokinetics, efficacy, and tolerability of DNX 
in AIDS-associated KS patients. Although response rates 
varied between trials, DNX proved superior to conventional 
DNR treatment and comparable to ABV (Gill et al 1996). 
The liposomal formulation stabilizes DNR, preventing rapid 
clearance and allowing more time for the drug to accumulate 
in KS lesions (Forssen et al 1992; Gill et al 1995). Notably, 
as observed with other liposomal anthracycline formulations, 
cardiotoxicity is limited even in the presence of high cumula-
tive DNR doses (500 mg/m2) (Gill et al 1995; Gill et al 1996; 
Tulpule et al 1998). Although DNX costs less per cycle than 
other liposomal anthracyclines on the market, indirect com-
parison suggests that PLD is actually more cost-effective due 
to an increased response rate (Bennett and Calhoun 2004). As 
both prior chemotherapeutic treatment as well as CD4 count 
have been reported to inﬂ  uence patient response to DNX (Gill 
et al 1995), it may be important to determine patient response 
in the context of naïve, CD4 high (>100/μL) individuals. In 
this setting, DNX may show signiﬁ  cant promise.
Currently Doxil (PLD) represents the major competitor to 
DNX therapy. In general, patient response to Doxil requires 
fewer treatment cycles and thus is more cost effective (Gill 
et al 1996; Stewart et al 1998; Bennett and Calhoun 2004). 
It is clear that the pegylated, STEALTH®, formulation of 
Doxil further limits RES uptake, resulting in longer periods 
of drug circulation in vivo (Allen and Martin 2004). Whether 
similar formulations of DNR would prove more efﬁ  cacious 
in the treatment of KS is unclear since anthracyclines dis-
play virtually identical mechanistic properties. Importantly, 
each new advance in liposomal technology has increased 
drug efﬁ  cacy, speciﬁ  city and tolerability, leading to better 
therapeutic options for patients with KS.
Strikingly, the efﬁ  cacy of DNX has been predominantly 
evaluated in the context of HIV-positive males. Although 
there is an urgency to develop more effective drugs for 
AIDS-associated KS, little is know about the effects of DNX 
on HIV-negative patients. Previous reports have observed no 
difference in the response rates of endemic vs epidemic KS International Journal of Nanomedicine 2007:2(3) 286
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to therapy (Stein et al 1994; Kigula-Mugambe and Kavuma 
2005). However, patient HIV status is sure to inﬂ  uence DNX 
efﬁ  cacy as CD4 count signiﬁ  cantly inﬂ  uences therapeutic 
outcome (Gill et al 1995). Clinical trials have thus far failed 
to address DNX efﬁ  cacy in females. In fact, less than 1% of 
DaunoXome study participants were female (Presant et al 
1993; Gill et al 1995, 1996; Tulpule et al 1998; Fumagalli 
et al 2000). These data reﬂ  ect the predominantly male HIV 
population at the outset of the AIDS epidemic in the US. To 
date, however, females account for almost half of the HIV-
positive population world-wide (Quinn and Overbaugh 2005; 
UNAIDS 2006). Over 25% of patients diagnosed with HIV in 
2004 were women and this number continues to grow (CDC 
2006). In areas where KS is endemic and spread by non-sexual 
as well as sexual routes, KS is found in women and female 
children almost as frequently as in men. As women often dis-
play differential drug metabolics, it is essential that additional 
studies be conducted in female KS patients in order to clearly 
understand and assess DNX efﬁ  cacy. 
Finally, use of universal response criteria, such as those 
provided by the ATCG or recently proposed (CIT-NEJM), 
should greatly improve our ability to assess therapeutic 
efﬁ  cacy. Proper assessment of visceral disease may require 
the advent of new technologies to improve KS detection 
and characterization. Additionally, future development of 
DaunoXome to decrease RES-uptake may be needed in 
order to compete with the pegylated anthracycline formula-
tions currently on the market. Still, DNX clearly represents a 
signiﬁ  cant advance in KS chemotherapy, providing multiple 
beneﬁ  ts over conventional, ABV-like therapies and poten-
tially improving patient QOL. 
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